FIELD: chemistry.
SUBSTANCE: invention refers to compounds of formula I or their pharmaceutically acceptable salts, which possess CDK4 kinase inhibiting activity. In formula IR1 and R2 are bound to a neighboring N atom, forming a C1-C8-alkyl substituted or unsubstituted 3–12-member saturated heterocycle, wherein said heterocycle refers to a ring structure containing 0–3 heteroatoms selected from a group consisting of N or O, in addition to a nitrogen atom attached to the nucleus; R3 is selected from C1-C8-alkyl, CN, CONR13R14, C(O)R15; R13 and R14 are independently selected from H or unsubstituted C1-C8-alkyl; R15 is selected from unsubstituted 3–12-membered saturated heterocycle, wherein said heterocycle contains at least one heteroatom selected from a group consisting of N and O; R4 is H; R5 is H; X is CR16; A, B and Z are independently selected from N or CR16; R16 is H or C1-C4-alkyl; L is absent or is C1-C6-alkylene; Y is where when W is O, then R6 is absent, when W is N, then R6 is H, unsubstituted C1-C8-alkyl or C(O)R24; R24 is unsubstituted C1-C8-alkoxy; R7 can be 0-3 substitutes, which are unsubstituted C1-C8-alkyl; Ya is N; n and t independently represent 0, 1 or 2.
EFFECT: invention also relates to a method of producing said compounds, use thereof for preparing a medicament for treating a disease associated with CDK4 kinase activity or expression value; for preparation of inhibitor, targeted CDK4 kinase; and/or for treating a disease associated with CDK4 kinase activity or expression value, a pharmaceutical composition and methods of inhibiting CDK4 kinase activity and tumor cells in vitro using said compounds.
10 cl, 2 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
CDK4/6 INHIBITOR | 2017 |
|
RU2747311C2 |
INHIBITORS OF CDK | 2011 |
|
RU2621674C2 |
PYRIMIDINE COMPOUND WITH CONDENSED RINGS, ITS INTERMEDIATE COMPOUND, METHOD OF PRODUCING, COMPOSITION AND USE | 2016 |
|
RU2732576C2 |
2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE OF SAID COMPOUND | 2015 |
|
RU2704129C2 |
HETEROCYCLIC COMPOUND USED AS A FGFR INHIBITOR | 2017 |
|
RU2742485C2 |
INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITORS, PREPARATION AND USE THEREOF | 2015 |
|
RU2719428C2 |
FGFR INHIBITOR AND ITS MEDICAL USE | 2018 |
|
RU2771311C2 |
COMPOUND AS CYCLIN-DEPENDENT KINASE 9 INHIBITOR AND USE THEREOF | 2020 |
|
RU2819762C1 |
TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DESTROYERS | 2017 |
|
RU2797244C2 |
ANTIVIRAL REMEDIES FOR TREATMENT AND PREVENTION OF HIV INFECTION | 2021 |
|
RU2780103C1 |
Authors
Dates
2019-06-13—Published
2016-04-15—Filed